MedTrace Logo

CfDNA in Hereditary And High-risk Malignancies 2

NCT06726642 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-12-16

No results posted yet for this study

Summary

The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will compare cancer detection rates between those receiving the new blood test and those receiving standard care, assess if the test leads to earlier cancer diagnosis, and evaluate its impact on patient outcomes. The study will also use questionnaires and interviews to understand how patients feel about the blood test, its incorporation into routine medical care, and perceptions of the medical value of test results. This research could lead to more effective and less invasive cancer screening for high-risk individuals.

Conditions

  • Hereditary Cancer Syndrome

Interventions

DIAGNOSTIC_TEST

Cell-free DNA analysis

Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).

Sponsors & Collaborators

  • British Columbia Cancer Agency

    collaborator OTHER

  • Eastern Health

    collaborator OTHER

  • IWK Health Centre

    collaborator OTHER

  • Jewish General Hospital

    collaborator OTHER

  • Sinai Health System

    collaborator OTHER

  • The Hospital for Sick Children

    collaborator OTHER

  • University of Alberta

    collaborator OTHER

  • Women's College Hospital

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Raymond Kim, MD · Princess Margaret Cancer Centre

Eligibility

Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-19
Primary Completion
2029-12-31
Completion
2031-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06726642 on ClinicalTrials.gov